Uchiyama M, Narita H, Makino M, Sekine H, Mori Y, Fukumitsu N, Kawakami K
Department of Radiology, Jikei University School of Medicine, Tokyo, Japan.
Clin Nucl Med. 1997 Sep;22(9):605-9. doi: 10.1097/00003072-199709000-00005.
The bone-seeking radiopharmaceutical Sr-89 has been used as a palliative treatment for patients with bone pain caused by bone metastases. The authors report the results of nine patients (three with prostate cancer, four with breast cancer, one with thyroid cancer, and one with lung cancer) who underwent therapy with Sr-89 chloride for painful bone metastases, and evaluate Sr-89 imaging with bremsstrahlung. Two levels of dosage (1.5 and 2.2 MBq/kg) were used. Sr-89 imaging was performed in seven patients 1 week after injection. Abnormal uptake was seen in all and was consistent with the results of Tc-99m HMDP imaging. Six patients were assessed at 3 months and three patients toward the time they were terminal; 78% (seven of nine) derived some benefit. Two patients had a favorable clinical response and showed improvement on Tc-99m HMDP imaging.
亲骨性放射性药物锶-89已被用作骨转移引起骨痛患者的姑息治疗。作者报告了9例接受氯化锶-89治疗骨转移性疼痛患者（3例前列腺癌、4例乳腺癌、1例甲状腺癌和1例肺癌）的结果，并评估了轫致辐射的锶-89成像。使用了两个剂量水平（1.5和2.2MBq/kg）。7例患者在注射后1周进行了锶-89成像。所有患者均可见异常摄取，且与锝-99m亚甲基二膦酸盐（Tc-99m HMDP）成像结果一致。6例患者在3个月时进行了评估，3例患者在临终时进行了评估；78%（9例中的7例）获得了一定益处。2例患者有良好的临床反应，且在Tc-99m HMDP成像上显示有所改善。
